$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo

$abeo Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222031655 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$68.00K
YoY Change	-97.73%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.682M	$3.890M	$6.092M
YoY Change	21.46%	-36.15%	37.52%
% of Gross Profit
Research & Development	$6.272M	$5.490M	$7.978M
YoY Change	-46.4%	-31.19%	0.1%
% of Gross Profit
Depreciation & Amortization	$729.0K	$780.0K	$802.0K
YoY Change	-9.67%	-2.74%	-5.65%
% of Gross Profit
Operating Expenses	$12.05M	$9.380M	$14.87M
YoY Change	-29.86%	-36.93%	12.24%
Operating Profit		-$9.380M	-$14.87M
YoY Change		-36.93%
Interest Expense	$150.0K	$157.0K	-$673.0K
YoY Change	-583.87%	-123.33%	-32.02%
% of Operating Profit
Other Income/Expense, Net	$11.66M	-$19.00K
YoY Change
Pretax Income	-$1.126M	-$9.484M	-$7.044M
YoY Change	-97.59%	34.64%	-2.71%
Income Tax
% Of Pretax Income
Net Earnings	-$1.126M	-$9.484M	-$7.044M
YoY Change	-97.59%	34.64%	-2.71%
Net Earnings / Revenue	-1655.88%
Basic Earnings Per Share		-$1.48	-$1.80
Diluted Earnings Per Share	-$0.08	-$1.477M	-$1.797M
COMMON SHARES
Basic Shares Outstanding	17.18M shares	5.950M shares	3.924M shares
Diluted Shares Outstanding		6.421M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$52.15M	$18.17M	$67.00M
YoY Change	15.82%	-72.88%	-30.86%
Cash & Equivalents	$14.22M	$5.733M	$43.78M
Short-Term Investments	$37.93M	$12.43M	$23.22M
Other Short-Term Assets	$762.0K	$6.283M	$907.0K
YoY Change	-89.67%	592.72%	29.57%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$188.0K	$1.047M
Total Short-Term Assets	$53.10M	$25.50M	$67.91M
YoY Change	-5.67%	-62.45%	-35.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.741M	$6.606M	$16.08M
YoY Change	-53.47%	-58.91%	-17.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$43.00K	$20.00K	$1.159M
YoY Change	-74.4%	-98.27%	5.36%
Total Long-Term Assets	$11.12M	$13.26M	$51.11M
YoY Change	-52.28%	-74.05%	-6.73%
TOTAL ASSETS
Total Short-Term Assets	$53.10M	$25.50M	$67.91M
Total Long-Term Assets	$11.12M	$13.26M	$51.11M
Total Assets	$64.21M	$38.76M	$119.0M
YoY Change	-19.31%	-67.43%	-25.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.811M	$1.748M	$1.861M
YoY Change	-58.13%	-6.07%	43.15%
Accrued Expenses	$3.991M	$4.121M	$4.316M
YoY Change	-28.54%	-4.52%	-18.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due			$0.00
YoY Change
Total Short-Term Liabilities	$7.779M	$12.60M	$26.47M
YoY Change	-53.2%	-52.4%	-31.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$200.0K	$12.80M
YoY Change		-98.44%	132.76%
Total Long-Term Liabilities	$0.00	$200.0K	$12.80M
YoY Change	-100.0%	-98.44%	132.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.779M	$12.60M	$26.47M
Total Long-Term Liabilities	$0.00	$200.0K	$12.80M
Total Liabilities	$37.45M	$23.35M	$39.28M
YoY Change	32.76%	-40.55%	-11.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$695.3M	-$694.2M
YoY Change	6.05%
Common Stock	$7.177M	$77.00K
YoY Change	387.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.76M	$15.41M	$79.74M
YoY Change
Total Liabilities & Shareholders Equity	$64.21M	$38.76M	$119.0M
YoY Change	-19.31%	-67.43%	-25.33%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$1.126M	-$9.484M	-$7.044M
YoY Change	-97.59%	34.64%	-2.71%
Depreciation, Depletion And Amortization	$729.0K	$780.0K	$802.0K
YoY Change	-9.67%	-2.74%	-5.65%
Cash From Operating Activities	-$13.99M	-$6.791M	-$10.33M
YoY Change	-53.76%	-34.28%	-3.42%
INVESTING ACTIVITIES
Capital Expenditures	$25.00K	-$2.000K	-$402.0K
YoY Change	-100.77%	-99.5%	48.89%
Acquisitions
YoY Change
Other Investing Activities	-$25.27M	$1.651M	$27.17M
YoY Change	-324.64%	-93.92%	458.95%
Cash From Investing Activities	-$25.29M	$1.649M	$26.76M
YoY Change	-416.16%	-93.84%	484.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	42.77M	4.189M	173.0K
YoY Change	161.87%	2321.39%
NET CHANGE
Cash From Operating Activities	-13.99M	-6.791M	-10.33M
Cash From Investing Activities	-25.29M	1.649M	26.76M
Cash From Financing Activities	42.77M	4.189M	173.0K
Net Change In Cash	3.484M	-953.0K	16.60M
YoY Change	-158.78%	-105.74%	-371.27%
FREE CASH FLOW
Cash From Operating Activities	-$13.99M	-$6.791M	-$10.33M
Capital Expenditures	$25.00K	-$2.000K	-$402.0K
Free Cash Flow	-$14.02M	-$6.789M	-$9.932M
YoY Change	-48.1%	-31.65%	-4.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0000318306
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent		usd
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2021Q3	us-gaap	Royalty Expense RoyaltyExpense		usd
	us-gaap	Royalty Expense RoyaltyExpense		usd
CY2022Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2021Q3	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
CY2022Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
CY2021Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
CY2021Q3	abeo	Impairment Of Constructioninprogress ImpairmentOfConstructioninprogress		usd
	abeo	Impairment Of Constructioninprogress ImpairmentOfConstructioninprogress		usd
CY2022Q3	abeo	Gain On Settlement Of Related Party GainOnSettlementOfRelatedParty		usd
	abeo	Gain On Settlement Of Related Party GainOnSettlementOfRelatedParty		usd
CY2022Q3	abeo	Ppp Loan Payable Forgiveness Income PppLoanPayableForgivenessIncome		usd
	abeo	Ppp Loan Payable Forgiveness Income PppLoanPayableForgivenessIncome		usd
CY2022Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2021Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit		usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit		usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited		usd
	abeo	Gain On Settlement Of Related Party GainOnSettlementOfRelatedParty		usd
	abeo	Ppp Loan Payable Forgiveness Income PppLoanPayableForgivenessIncome		usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill		usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges		usd
	abeo	Noncash Interest NoncashInterest		usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock		usd
	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain		usd
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss		usd
CY2022Q3	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2021Q4	abeo	Finite Lived Impairment Charge FiniteLivedImpairmentCharge		usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2022Q3	abeo	Accrued Sublicense Fee Owed To Licensor AccruedSublicenseFeeOwedToLicensor		usd
CY2022Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-15771
	dei	Entity Registrant Name EntityRegistrantName	ABEONA THERAPEUTICS INC
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-0221517
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1330 Avenue of the Americas
	dei	Entity Address Address Line2 EntityAddressAddressLine2	33rd Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10019
	dei	City Area Code CityAreaCode	(646)
	dei	Local Phone Number LocalPhoneNumber	813-4701
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value
	dei	Trading Symbol TradingSymbol	ABEO
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17175799	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5733000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32938000	usd
CY2022Q3	us-gaap	Short Term Investments ShortTermInvestments	12434000	usd
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	12086000	usd
CY2022Q3	us-gaap	Restricted Cash RestrictedCash	5338000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	5891000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3000000	usd
CY2022Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1047000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	945000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2377000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	25497000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	56292000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6606000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12339000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6638000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9403000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1384000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	168000	usd
CY2022Q3	us-gaap	Assets Assets	38761000	usd
CY2021Q4	us-gaap	Assets Assets	79586000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1748000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4325000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4121000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5585000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1810000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1818000	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	4921000	usd
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	4599000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	296000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	12600000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16623000	usd
CY2022Q3	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	4064000	usd
CY2021Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	3828000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	200000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	200000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6484000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7560000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	23348000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	28211000	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7671351	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7671351	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5888217	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5888217	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	77000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1472000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	709590000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	705570000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-694210000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-655640000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-44000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-27000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	15413000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	51375000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	38761000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	79586000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1346000	usd
	us-gaap	Royalty Expense RoyaltyExpense	350000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5490000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9056000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22693000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25923000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3890000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5816000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11574000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17261000	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	1355000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1561000	usd
	abeo	Impairment Of Constructioninprogress ImpairmentOfConstructioninprogress	-1792000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	9380000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	14872000	usd
	us-gaap	Operating Expenses OperatingExpenses	39325000	usd
	us-gaap	Operating Expenses OperatingExpenses	43184000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9380000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-14872000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-37979000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-43184000	usd
CY2021Q3	abeo	Gain On Settlement Of Related Party GainOnSettlementOfRelatedParty	6743000	usd
	abeo	Gain On Settlement Of Related Party GainOnSettlementOfRelatedParty	6743000	usd
CY2021Q3	abeo	Ppp Loan Payable Forgiveness Income PppLoanPayableForgivenessIncome	1758000	usd
	abeo	Ppp Loan Payable Forgiveness Income PppLoanPayableForgivenessIncome	1758000	usd
CY2022Q3	us-gaap	Interest Income Operating InterestIncomeOperating	72000	usd
CY2021Q3	us-gaap	Interest Income Operating InterestIncomeOperating	7000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	103000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	35000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	157000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	683000	usd
	us-gaap	Interest Expense InterestExpense	558000	usd
	us-gaap	Interest Expense InterestExpense	3603000	usd
CY2022Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-19000	usd
CY2021Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	3000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-136000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-2000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-9484000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-7044000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-38570000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-38253000	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	3782000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9484000	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7044000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42352000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-38253000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.48
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.80
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.93
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6421245	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3924024	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6009902	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3853318	shares
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-11000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	10000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-6000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-9000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-6000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-9000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9494000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7052000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42369000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38252000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	20086000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	632000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4189000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-9484000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-10000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	15413000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	51375000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2218000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4189000	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	3782000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-38570000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-17000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	15413000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	84086000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2537000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	33000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	140000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-7044000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-8000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	79744000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	102551000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6915000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7699000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	831000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-38253000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	79744000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-38570000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-38253000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2364000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2443000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2218000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6915000	usd
	abeo	Gain On Settlement Of Related Party GainOnSettlementOfRelatedParty	6743000	usd
	abeo	Ppp Loan Payable Forgiveness Income PppLoanPayableForgivenessIncome	1758000	usd
	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	1355000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1561000	usd
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	1792000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	206000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-256000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1204000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	825000	usd
	abeo	Noncash Interest NoncashInterest	558000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-121000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3000000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1047000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1432000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1801000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-148000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	23000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-5125000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4459000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-296000	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	3588000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29491000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-35408000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	105000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	903000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1590000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	43866000	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	15164000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	43707000	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	74130000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1326000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	58063000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4189000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7699000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	831000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	22468000	usd
	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	26250000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	407000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8530000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-27758000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31185000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	38829000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13571000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11071000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	44756000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5733000	usd
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43781000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	5338000	usd
CY2021Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	975000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11071000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44756000	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	exchange ratio of 25-to-1 (the “Reverse Stock Split”)
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_84A_eus-gaap--BasisOfAccounting_zL2v3rGIZHUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z2AT0GNiI2Ha">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s unaudited interim condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, except as otherwise disclosed, necessary for the fair presentation of the financial position, results of operations, and changes in financial position for such periods, have been made. These unaudited interim condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. Certain information that is normally required by U.S. GAAP has been condensed or omitted in accordance with rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The December 31, 2021 condensed consolidated balance sheet was derived from the audited statements, but does not include all disclosures required by U.S. GAAP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therefore, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	23500000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29500000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zIKEFedS2dDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zxOEEpkAqONi">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and disclosure of contingent assets and liabilities at the date of the unaudited interim condensed consolidated financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from these estimates and assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zNJNEtOYRwrg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z6p2o7q3NbA4">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain comparative figures have been reclassified to conform to the current year presentation. The Company reclassified depreciation and amortization costs of $<span id="xdx_90C_eus-gaap--DepreciationDepletionAndAmortization_pn5n6_c20210701__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zvfz5K7mocP8" title="Depreciation and amortization costs">0.8</span> million and $<span id="xdx_905_eus-gaap--DepreciationDepletionAndAmortization_c20210701__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7UcGgTZjgVb" title="Depreciation and amortization costs">16,000</span> to research and development and general and administrative expenses, respectively, on the condensed consolidated statements of operations and comprehensive loss during the three months ended September 30, 2021. The Company reclassified depreciation and amortization costs of $<span id="xdx_902_eus-gaap--DepreciationDepletionAndAmortization_pn5n6_c20210101__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z80saVAJH9bi" title="Depreciation and amortization costs">2.4</span> million and $<span id="xdx_907_eus-gaap--DepreciationDepletionAndAmortization_c20210101__20210930__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zEnaU6GurNXe" title="Depreciation and amortization costs">49,000</span> to research and development and general and administrative expenses, respectively, on the condensed consolidated statements of operations and comprehensive loss during the nine months ended September 30, 2021. The Company also reclassified certain rent expenses of $<span id="xdx_905_ecustom--RentExpense_pn5n6_c20210701__20210930__us-gaap--ReclassificationTypeAxis__custom--GeneralAndAdministrativeToResearchAndDevelopmentExpensesMember_zEFE6TH0y8Qk" title="Reclassification of Rent expense">0.3</span> million and $<span id="xdx_900_ecustom--RentExpense_pn5n6_c20210101__20210930__us-gaap--ReclassificationTypeAxis__custom--GeneralAndAdministrativeToResearchAndDevelopmentExpensesMember_zM8DomrMYbO8" title="Reclassification of Rent expense">0.9</span> million from general and administrative to research and development expenses on the condensed consolidated statements of operations and comprehensive loss during the three and nine months ended September 30, 2021, respectively. Additionally, the Company also reclassified $<span id="xdx_90C_eus-gaap--RestrictedCash_iI_pn6n6_c20211231__us-gaap--ReclassificationTypeAxis__custom--PrepaidExpensesOtherCurrentAssetsToRestrictedCashMember_zFsRcoGnopL2" title="Restricted cash">5.0</span> million of restricted cash from prepaid expenses, other current assets and restricted cash and $<span id="xdx_90C_eus-gaap--RestrictedCash_iI_pn5n6_c20211231__us-gaap--ReclassificationTypeAxis__custom--OtherAssetsAndRestrictedCashToRestrictedCashMember_z2b62xWSWtFj" title="Restricted cash">0.9</span> million of restricted cash from other assets and restricted cash to restricted cash on the condensed consolidated balance sheets as of December 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2851913	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2851913	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	424417	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	424417	shares
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	12445000	usd
	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	11000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	12434000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	12077000	usd
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Gain AvailableForSaleDebtSecuritiesGrossUnrealizedGain	9000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	12086000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2021Q3	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18456000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22799000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11850000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10460000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6606000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12339000	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	800000	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	800000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2300000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2400000	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	1800000	usd
	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	1400000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2156000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2156000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	801000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	772000	usd
CY2022Q3	abeo	Finite Lived Impairment Charge FiniteLivedImpairmentCharge	1355000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1384000	usd
CY2022Q2	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	26300000	usd
	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	the Company’s stock underwent a 25:1 Reverse Stock Split
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1788000	shares
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.75
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_80F_eus-gaap--LossContingencyDisclosures_zlhL3akwG0Ne" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_821_zCYkOSEIWJa">SETTLEMENT LIABILITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 12, 2021, the Company entered into a settlement agreement (“Settlement Agreement”) with the Company’s prior licensor REGENXBIO Inc. (“REGENXBIO”) to resolve all existing disputes between the parties. In accordance with the Settlement Agreement, the Company agreed to pay REGENXBIO a total of $<span id="xdx_909_eus-gaap--SettlementLiabilitiesCurrent_iI_pn6n6_c20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zniRXQlxTN28" title="Settlement Liabilities, Current">30.0</span> million, payable as follows: <span id="xdx_904_eus-gaap--LossContingencySettlementAgreementTerms_c20211111__20211112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zmwiqEZFrPwh" title="Loss Contingency, Settlement Agreement, Terms">(1) $20.0 million paid in November 2021 after execution of the Settlement Agreement, (2) $5.0 million on the first anniversary of the effective date of the Settlement Agreement, and (3) $5.0 million upon the earlier of (i) the third anniversary of the effective date of the Settlement Agreement or (ii) the closing of a Strategic Transaction, as defined in the Settlement Agreement</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2022, the Company recorded the payables due to REGENXBIO in the condensed consolidated balance sheets based on the present value of the remaining payments due to REGENXBIO under the Settlement Agreement using an interest rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zqJuJS7D7xt3" title="Debt Instrument, Interest Rate, Stated Percentage">9.6</span>%. The current portion of the payable due in <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--DebtInstrumentAxis__custom--DueInNovemberTwoThousandAndTwentyTwoMember_zPZiO7wIILjk" title="Debt instrument maturity date">November 2022</span> is $<span id="xdx_907_eus-gaap--LongTermDebt_iI_pn5n6_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--DebtInstrumentAxis__custom--DueInNovemberTwoThousandAndTwentyTwoMember_z3sLRXZDGAL4" title="Long term debt">4.9</span> million and the long-term portion due in <span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--DebtInstrumentAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_zkwrXS9IQoT6" title="Debt instrument maturity date">November 2024</span> is $<span id="xdx_908_eus-gaap--LongTermDebt_iI_pn5n6_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember__us-gaap--DebtInstrumentAxis__custom--DueInNovemberTwoThousandAndTwentyFourMember_zM9ABgOQDDw9" title="Long term debt">4.1</span> million as of September 30, 2022. As of September 30, 2022, the Company recorded $<span id="xdx_908_eus-gaap--RestrictedCash_iI_pn6n6_c20220930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--REGENXBIOMember_zlI69pendpbd" title="Restricted Cash">5.0</span> million of restricted cash in the condensed consolidated balance sheet that serves as collateral for the payment owed to REGENXBIO in November 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	42060000	usd
CY2022Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	2092000	usd
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1794000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2029000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3091000	usd
CY2021Q4	abeo	Accrued Sublicense Fee Owed To Licensor AccruedSublicenseFeeOwedToLicensor	700000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4121000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5585000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1600000	usd
	us-gaap	Preferred Stock Redemption Terms PreferredStockRedemptionTerms	The holders of the Series A Preferred Stock and Series B Preferred Stock had the right to require the Company to redeem their shares of preferred stock for cash at 105% of the stated value of such shares commencing after the earlier of the receipt of stockholder approval of an amendment to the Company’s Restated Certificate of Incorporation to effect a reverse stock split and 60 days after the closing of the issuances of the Series A Preferred Stock and Series B Preferred Stock and until 90 days after such closing. The Company had the option to redeem the Series A Preferred Stock for cash at 105% of the stated value commencing after the 90th day following the closing of the issuance of the Series A Preferred Stock, subject to the holders’ rights to convert the shares prior to such redemption
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	467000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	434000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1400000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1302000	usd
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	154000	usd
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	105000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	366000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	344000	usd
CY2022Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	17000	usd
CY2021Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	13000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	58000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	23000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	638000	usd
CY2021Q3	us-gaap	Lease Cost LeaseCost	552000	usd
	us-gaap	Lease Cost LeaseCost	1824000	usd
	us-gaap	Lease Cost LeaseCost	1669000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	446000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1829000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1872000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1631000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	871000	usd
CY2022Q3	abeo	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	3662000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10311000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2017000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	8294000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P79M
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.072	pure
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	632000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2537000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2218000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6915000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	4100000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P3Y1M6D
	abeo	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue	1300000	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	25000000.0	usd
CY2022Q3	us-gaap	Share Price SharePrice	19.00
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	22500000	usd
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	3800000	usd
CY2022Q3	us-gaap	Escrow Deposit EscrowDeposit	26300000	usd
CY2022Q3	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	11.25
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	3800000	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1788000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.75
CY2021Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	16000000.0	usd
CY2021Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1500000	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1788000	shares
CY2022Q3	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2026-12-21

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
abeo-20220930_lab.xml	Edgar Link	unprocessable
0001493152-22-031655-index-headers.html	Edgar Link	pending
0001493152-22-031655-index.html	Edgar Link	pending
0001493152-22-031655.txt	Edgar Link	pending
0001493152-22-031655-xbrl.zip	Edgar Link	pending
abeo-20220930.xsd	Edgar Link	pending
ex-32.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
abeo-20220930_def.xml	Edgar Link	unprocessable
abeo-20220930_cal.xml	Edgar Link	unprocessable
abeo-20220930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo

2022 Q4 Form 10-Q Financial Statement

#000149315222031655 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABEO ABEONA THERAPEUTICS INC. Stock $abeo

2022 Q4 Form 10-Q Financial Statement

#000149315222031655 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABEO
ABEONA THERAPEUTICS INC. Stock $abeo